Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled cardiovascular outcomes study of enlicitide decanoate (MK-0616) in high-risk ASCVD
2022-502781-24-01Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hypercholesterolemia comparing Enlicitide decanoate with Placebo (2 arms). Primary endpoint: Time to first occurrence of CHD death-based MACE-Plus. Planned start Jun 2024; status: authorised.
02
Drugs
enlicitide
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on 2022-502781-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502781-24-01.